Navigating the Complexity of Chronic Graft-vs-Host Disease: Canadian Insights into Real-World Treatment Sequencing
Transplantation Proceedings · 2024
DOI: 10.1016/j.transproceed.2023.12.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation Proceedings, 2024. Verfasst von Dennis Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Center, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Photopheresis, Nitriles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Graft-vs-Host Disease (GVHD) is a donor immune-mediated syndrome occurring in patients who undergo an allogeneic hematopoietic cell transplant (HCT). Chronic GVHD (cGVHD) presents with complications of variable severity. Corticosteroids are standard first-line (1L) treatment, but the sequence after 1L is unclear with the availability of new treatments. This research aimed to understand real-world treatment sequencing for cGVHD. METHODS: This retrospective study investigated adult patients across 7 treatment sites in Canada who had received an allogeneic HCT >18 months prior to the study, experienced cGVHD, and received systemic treatment, including extracorporeal photopheresis (ECP). RESULTS: A total of 77 cases were reviewed retrospectively (median age = 51 (IQR 41-62), 51% female). 59 patients remained on active systemic treatment, and among this group, the most common treatments in use were corticosteroids (47%) and ruxolitinib (47%). One patient died, and 17 patients were on non-systemic treatment after complications resolved. The median lines of treatment (LOT) received was 2 (IQR 1-3), with 39% of patients having received >2 LOT. Among patients with lung complications (n = 24), 41% had received 3 or more LOT. Among patients with scleroderma (n = 22), 77% had received 3 or more LOT, 23% of which had received 6 or more unique treatments. CONCLUSIONS: The first treatment given to cGVHD patients was corticosteroids. Ruxolitinib was the most used second-line treatment. About 40% of cGVHD patients received >2 treatments, and scleroderma was associated with more LOT. There is a need for more effective cGVHD treatment options when early treatments fail to resolve complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Princess Margaret Cancer Center, Toronto, Ontario, Canada.
- University of Alberta Health Sciences Centre, Edmonton, Alberta, Canada.
- Drug Intelligence, Toronto, Ontario, Canada. Electronic address: erobinson@drugintelligence.com.
- Drug Intelligence, Toronto, Ontario, Canada.
Zitieren
APA
Kim, D., Taparia, M., Robinson, E., Mcgee, M., & Merali, T. (2024). Navigating the Complexity of Chronic Graft-vs-Host Disease: Canadian Insights into Real-World Treatment Sequencing. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2023.12.021
Vancouver
Kim D, Taparia M, Robinson E, Mcgee M, Merali T. Navigating the Complexity of Chronic Graft-vs-Host Disease: Canadian Insights into Real-World Treatment Sequencing. Transplantation Proceedings. 2024. doi:10.1016/j.transproceed.2023.12.021
BibTeX
@article{Kim2024,
author = {Kim, Dennis and Taparia, Minakshi and Robinson, Erika and Mcgee, Meghan and Merali, Tazmin},
title = {Navigating the Complexity of Chronic Graft-vs-Host Disease: Canadian Insights into Real-World Treatment Sequencing},
journal = {Transplantation Proceedings},
year = {2024},
doi = {10.1016/j.transproceed.2023.12.021}
}
EUVIMED